Posted by Michael Wonder on 06 Apr 2017
Pharma warns new NICE rules will delay access to medicines
3 April 2017 - Pharma companies are warning that changes to the way the National Institute for Health & Care Excellence (NICE) and NHS England (NHSE) assess new medicines, which came into affect on April 1, will hinder patient access to the latest treatments.
In a survey of member companies of the Association of the British Pharmaceutical Industry (ABPI), 71% said they believe that the new system will see their companies prioritise the launch of new medicines in European countries over the UK, while 89% said patient access to cost-effective medicines in the UK will decrease as a result.
